GLP-1 receptor agonists × quality of life & behaviour

TrialDiabetes, obesity & metabolism2019

Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.

Michael A Nauck et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2019

Randomised comparison

Probably raised quality of life & behaviour

+0.02+0.00 to +0.04

As reported

difference 0.023, 95% CI 0.00–0.04

One number in the abstract

the abstract, start to end

estimated treatment difference [ETD] 0.023, 95% confidence interval [CI]

← favours treatmentfavours comparator →
could be chance
Quality of life & behaviour
0.0230.00–0.04
GLP-1 receptor agonistsQuality of life & behaviour

GLP-1 receptor agonists × quality of life & behaviourhelps?mixed

unlikelylikely
0.440.37 without it
← favours comparatorfavours treatment →
this papermore certainless certain
1 / 5

20 papers cite it

2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 30260088